Pharmaceutical glass packaging market is set to reach US$ 37.62 billion by 2030, at a CAGR of 9.8%. Asia Pacific leads the market with 39% market share.

The Pharmaceutical glass packaging market size was estimated at USD 19.75 billion in 2023 and is projected to reach USD 37.62 billion by 2030, growing at a CAGR of 9.8% from 2024 to 2030. Extensive utilization of generic injectable drugs, coupled with high demand from the pharmaceutical industry, is anticipated to drive market growth.

Pharmaceutical glass packaging refers to specialized glass containers designed to safely store, protect, and preserve medicines, vaccines, and biologics, ensuring chemical stability, sterility, and extended shelf life across global markets.

DataM Intelligence unveils its latest report on the "Pharmaceutical glass packaging Market size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/pharmaceutical-glass-packaging-market?prtk

United States: Key Industry Developments (2025)

✅ October 2025: At CPHI Frankfurt 2025, SGD Pharma highlighted its Sealian platform, an innovative internal surface treatment for molded glass vials designed to enhance container integrity and reduce drug‐glass interactions, plus expanded analytical Lab Services for glass packaging validation.

✅ June-August 2025: Gerresheimer introduced a new range of highly resistant glass vials with a silicon‐free coating that minimizes drug‐container interactions, aimed at improving biologic drug safety and expected to cover 12% of the firm's production by year‐end.

✅ March 2025: During DCAT Week 2025 in New York, SGD Pharma emphasized sustainable, high‐precision vial production and decarbonized furnace upgrades to meet increasing U.S. pharma demand for robust glass primary packaging.

Japan: Key Industry Developments (2025)

✅ December 2025: Nippon Electric Glass (NEG) began mass production of pharmaceutical glass tubing using an all‐electric melting furnace technology, significantly reducing CO2 emissions (up to 90%) and advancing low‐carbon glass production for vials and ampoules.

✅ September 2025: China‐based LINUO announced a major 2 billion RMB investment project in high‐end borosilicate pharmaceutical glass packaging, integrating automation and intelligent manufacturing to boost precision and output for glass container production.

✅ July 2025: Mitsubishi Gas Chemical (MGC) received the Packaging Innovation Award at Pharmapack 2025 for its OXYCAPTTM container, a high‐barrier three‐layer vial solution combining excellent gas and UV protection with improved durability targeting sensitive biologic therapies.

📌 Pharmaceutical glass packaging Market 2025-26 M&A Deals

→ In August 2025, SGD Pharma (a global pharmaceutical glass packaging provider) acquired Alphial S.r.l., an Italy‐based manufacturer of tubular vials, ampoules and ready‐to‐use (RTU) glass packaging, from private equity owners including Entangled Capital and Capital Dynamics. The financial terms were not publicly disclosed. This strategic acquisition is intended to expand SGD Pharma's tubular glass converting capabilities and strengthen its European and global pharmaceutical packaging footprint.

→ In May 2025, TPG Growth, the growth equity arm of TPG, agreed to acquire a 35% stake in SCHOTT Poonawalla, a leading drug containment and injectable packaging joint venture between SCHOTT Pharma AG and the Serum Institute of India, with Novo Holdings co‐investing. The investment was valued at approximately $300 million and aims to support capacity expansion and innovation in primary packaging for injectable biologics and other sensitive pharmaceuticals.

Pharmaceutical glass packaging Market Drivers:-
⏩ Demand for glass containers for sterile injectable drugs expanded meaningfully as global injectable doses climbed, with biologics representing a significant share of these therapies.

⏩ Prefilled glass syringes reached 4.7 billion units in 2023, up ~6% year‐on‐year, reflecting a strong trend toward patient‐friendly, ready‐to‐use formats.

⏩ Influenza and pandemic vaccine programs have historically placed unprecedented demand on pharmaceutical glass supplies, requiring billions of reliable sterile vials.

⏩ Regulatory requirements effectively mandate Type I borosilicate glass chosen for chemical inertness, durability, and temperature resistance for many sterile drug products.

⏩ Audits and updated standards (e.g., USP and ISO) have increased compliance rigor, incentivizing investments in high‐quality glass solutions.

⏩ Biologics highly sensitive to environmental stress need inert packaging: glass vials, cartridges, and syringes with low extractables are ideal.

⏩ Growth of chronic disease therapies (e.g., diabetes, oncology) has boosted demand for cartridge‐based injectable packaging, which saw rising adoption owing to patient self‐administration trends.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=pharmaceutical-glass-packaging-market?prtk

Pharmaceutical glass packaging Major Players:-
Corning Incorporated, SCHOTT AG, Amcor plc, NIPRO, SGD Pharma, Stoelzle Glass Group, Bormioli Pharma S.p.A., West Pharmaceutical Services, Beatson Clark, APG Europe.

Key players highlights:-
Schott AG - ~29% market share
German specialty glass leader known for borosilicate glass solutions used in vials and ampoules for global pharma markets. Dominates through high‐quality, chemically resistant glass and extensive R&D.

Corning Incorporated - ~22% market share
U.S. materials science company innovating Valor® and coated glass technologies that improve durability and fill‐finish performance. Strong partnerships with major pharma firms underpin global reach.

Nipro Corporation - ~9.6% market share
Japan‐based manufacturer of Type I glass vials, ampoules and prefillable systems with facilities across Europe and the U.S. Focuses on quality, regulatory compliance, and custom pharma glass solutions.

SGD Pharma - ~5.8% market share
French glass packaging specialist providing a full range of borosilicate glass containers for injectable drugs worldwide. Investing in expanded capacity and joint ventures to enhance production footprint.

West Pharmaceutical Services - ~6.0% market share
U.S. company offering containment and delivery systems alongside glass packaging interfaces for injectable therapies. Known for integrated solutions that support filling and closure technologies.

Pharmaceutical glass packaging Regional Highlights
North America
• North America holds 35% of the global pharmaceutical glass packaging market share, led by the U.S. with strong pharmaceutical production and R&D infrastructure.
• High adoption of injectable therapies and advanced packaging technologies supports sustained demand.
• The region's growth is driven by stringent regulations, biologics manufacturing, and expansion of generics requiring sterile glass containers.

Europe
• Europe contributes roughly 29% of the global market share, supported by established pharmaceutical manufacturing clusters.
• Regulatory emphasis on quality and sustainability increases demand for high‐grade glass vials and cartridges.
• Growth is underpinned by strong exports of biologics and specialty drugs from countries like Germany and France.

Asia Pacific
• Asia Pacific accounts for 39% of global pharmaceutical glass packaging share, often the largest regional share in recent data.
• Rapid expansion of pharmaceutical manufacturing in China and India drives strong demand for glass packaging.
• Increasing healthcare expenditure, vaccine production, and export growth boost regional market development.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/pharmaceutical-glass-packaging-market?prtk

Pharmaceutical glass packaging segmentation :
The Pharmaceutical Glass Packaging market is segmented based on product, drug type, and application. By product, it includes vials, bottles, cartridges and syringes, ampoules, and others, catering to diverse packaging needs. By drug type, it covers generic, branded, and biologic drugs, reflecting different formulation requirements. By application, the market serves biopharmaceutical and biotechnology companies, research organizations, and other end-users, highlighting its broad adoption across the pharmaceutical and life sciences sectors.

FAQ'S
Q: What are the key types of pharmaceutical glass packaging?
A: Vials, bottles, ampoules, cartridges, syringes, and other specialty glass containers.

Q: Which factors are driving growth in the pharmaceutical glass packaging market?
A: Increasing biologics production, stringent regulatory standards, and rising demand for safe drug storage.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.